AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology. The buyout is designed to strengthen MedImmune’s cancer-related research, and includes an initial payment of $225 million, with the possibility of another […]
bahija jallall
August 29, 2013 |
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia